| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 10 | 2019 | 799 | 1.350 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 16 | 2023 | 889 | 1.350 |
Why?
|
| Programmed Cell Death 1 Receptor | 7 | 2023 | 173 | 1.280 |
Why?
|
| Immunotherapy | 8 | 2023 | 698 | 1.250 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2016 | 312 | 1.040 |
Why?
|
| Immune Tolerance | 5 | 2017 | 341 | 1.030 |
Why?
|
| T-Lymphocytes | 11 | 2021 | 1221 | 1.020 |
Why?
|
| Antibodies, Monoclonal | 7 | 2023 | 1396 | 0.910 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2021 | 153 | 0.910 |
Why?
|
| Transplantation Conditioning | 13 | 2020 | 373 | 0.900 |
Why?
|
| B7-H1 Antigen | 6 | 2020 | 278 | 0.890 |
Why?
|
| Lymphoma | 4 | 2020 | 266 | 0.870 |
Why?
|
| Hodgkin Disease | 2 | 2017 | 181 | 0.830 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2021 | 197 | 0.780 |
Why?
|
| Melanoma, Experimental | 3 | 2014 | 111 | 0.770 |
Why?
|
| Tumor Escape | 2 | 2020 | 51 | 0.750 |
Why?
|
| Antigen-Presenting Cells | 3 | 2017 | 142 | 0.740 |
Why?
|
| Graft vs Host Disease | 9 | 2020 | 358 | 0.740 |
Why?
|
| Leukemia | 4 | 2017 | 322 | 0.700 |
Why?
|
| Antineoplastic Agents | 10 | 2023 | 2331 | 0.680 |
Why?
|
| Homeostasis | 3 | 2012 | 418 | 0.650 |
Why?
|
| Cell Proliferation | 5 | 2016 | 1670 | 0.650 |
Why?
|
| Lymphoma, B-Cell | 1 | 2020 | 107 | 0.640 |
Why?
|
| Neoplasms | 8 | 2018 | 3065 | 0.620 |
Why?
|
| Arabinonucleosides | 3 | 2011 | 39 | 0.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 2506 | 0.560 |
Why?
|
| Immune Evasion | 1 | 2017 | 35 | 0.560 |
Why?
|
| Transplantation, Homologous | 16 | 2020 | 995 | 0.520 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2013 | 261 | 0.500 |
Why?
|
| Immunity, Innate | 3 | 2016 | 434 | 0.500 |
Why?
|
| Lymphocyte Activation | 4 | 2016 | 754 | 0.500 |
Why?
|
| Hematologic Neoplasms | 5 | 2023 | 344 | 0.470 |
Why?
|
| Lymphocyte Depletion | 4 | 2017 | 98 | 0.460 |
Why?
|
| Thymus Gland | 1 | 2014 | 197 | 0.440 |
Why?
|
| CD40 Antigens | 1 | 2013 | 44 | 0.430 |
Why?
|
| Signal Transduction | 5 | 2017 | 3404 | 0.410 |
Why?
|
| Geriatric Assessment | 4 | 2020 | 182 | 0.410 |
Why?
|
| Tumor Microenvironment | 4 | 2023 | 476 | 0.410 |
Why?
|
| Cross-Priming | 1 | 2012 | 49 | 0.390 |
Why?
|
| Graft vs Tumor Effect | 2 | 2010 | 24 | 0.390 |
Why?
|
| Animals | 21 | 2020 | 27528 | 0.380 |
Why?
|
| B7-1 Antigen | 3 | 2016 | 76 | 0.380 |
Why?
|
| Antigen Presentation | 3 | 2020 | 215 | 0.370 |
Why?
|
| Mice, Inbred C57BL | 9 | 2016 | 3252 | 0.370 |
Why?
|
| Adenine Nucleotides | 2 | 2011 | 63 | 0.350 |
Why?
|
| Humans | 47 | 2023 | 89961 | 0.350 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 111 | 0.340 |
Why?
|
| Cord Blood Stem Cell Transplantation | 4 | 2017 | 91 | 0.340 |
Why?
|
| Antibodies, Neoplasm | 2 | 2009 | 84 | 0.330 |
Why?
|
| Membrane Proteins | 1 | 2016 | 1227 | 0.330 |
Why?
|
| Cell Differentiation | 3 | 2016 | 1533 | 0.330 |
Why?
|
| WT1 Proteins | 1 | 2009 | 20 | 0.320 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2016 | 600 | 0.320 |
Why?
|
| Salvage Therapy | 1 | 2010 | 230 | 0.320 |
Why?
|
| Rituximab | 4 | 2023 | 117 | 0.320 |
Why?
|
| Antigens, Differentiation | 1 | 2009 | 141 | 0.320 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2009 | 215 | 0.310 |
Why?
|
| Mice | 14 | 2016 | 11851 | 0.310 |
Why?
|
| Mice, Knockout | 7 | 2016 | 2016 | 0.290 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 432 | 0.280 |
Why?
|
| Leukemia, T-Cell | 1 | 2006 | 17 | 0.270 |
Why?
|
| Flow Cytometry | 4 | 2013 | 690 | 0.260 |
Why?
|
| Ganciclovir | 1 | 2006 | 49 | 0.260 |
Why?
|
| Valine | 1 | 2006 | 62 | 0.260 |
Why?
|
| CD47 Antigen | 2 | 2016 | 23 | 0.260 |
Why?
|
| Antiviral Agents | 2 | 2007 | 482 | 0.260 |
Why?
|
| Peptides | 1 | 2009 | 649 | 0.250 |
Why?
|
| Acyclovir | 1 | 2006 | 108 | 0.250 |
Why?
|
| Bone Marrow Transplantation | 1 | 2006 | 283 | 0.240 |
Why?
|
| Cytomegalovirus Infections | 1 | 2006 | 150 | 0.240 |
Why?
|
| Middle Aged | 23 | 2019 | 26146 | 0.230 |
Why?
|
| Aged | 22 | 2020 | 19254 | 0.230 |
Why?
|
| Transplantation, Autologous | 4 | 2020 | 347 | 0.230 |
Why?
|
| Survival Analysis | 6 | 2017 | 1497 | 0.220 |
Why?
|
| Lymphoma, Follicular | 1 | 2023 | 73 | 0.210 |
Why?
|
| Interferon Type I | 2 | 2016 | 186 | 0.210 |
Why?
|
| Male | 25 | 2020 | 42674 | 0.210 |
Why?
|
| Self Tolerance | 2 | 2016 | 25 | 0.200 |
Why?
|
| Cell Separation | 2 | 2013 | 199 | 0.200 |
Why?
|
| Antigens, Neoplasm | 2 | 2016 | 334 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 76 | 0.200 |
Why?
|
| Histiocytes | 1 | 2021 | 22 | 0.190 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2012 | 65 | 0.190 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 399 | 0.190 |
Why?
|
| Cell Line, Tumor | 5 | 2016 | 2586 | 0.190 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 47 | 0.190 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2021 | 51 | 0.190 |
Why?
|
| Adult | 18 | 2019 | 26816 | 0.180 |
Why?
|
| Disease Models, Animal | 3 | 2016 | 2393 | 0.180 |
Why?
|
| Interferon-gamma | 3 | 2013 | 449 | 0.180 |
Why?
|
| Dendritic Cells | 2 | 2016 | 451 | 0.180 |
Why?
|
| Recurrence | 4 | 2017 | 1145 | 0.170 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2019 | 5 | 0.170 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 158 | 0.170 |
Why?
|
| Galectins | 1 | 2019 | 11 | 0.170 |
Why?
|
| Hydrazines | 1 | 2019 | 31 | 0.170 |
Why?
|
| Female | 23 | 2020 | 46587 | 0.160 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2017 | 359 | 0.160 |
Why?
|
| Mitoxantrone | 1 | 2019 | 67 | 0.160 |
Why?
|
| Fetal Blood | 2 | 2017 | 93 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2010 | 1134 | 0.160 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 131 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 1284 | 0.160 |
Why?
|
| Cytarabine | 1 | 2019 | 219 | 0.160 |
Why?
|
| Triazoles | 1 | 2019 | 104 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 1352 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 126 | 0.150 |
Why?
|
| Melphalan | 2 | 2023 | 98 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 194 | 0.150 |
Why?
|
| Clonal Anergy | 2 | 2008 | 31 | 0.140 |
Why?
|
| Treatment Outcome | 8 | 2019 | 8273 | 0.140 |
Why?
|
| Preoperative Care | 1 | 2019 | 395 | 0.140 |
Why?
|
| Disease Management | 1 | 2019 | 327 | 0.140 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2017 | 19 | 0.140 |
Why?
|
| Remission Induction | 2 | 2017 | 741 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2019 | 284 | 0.140 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 785 | 0.140 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2015 | 93 | 0.140 |
Why?
|
| Health Services Misuse | 1 | 2016 | 20 | 0.140 |
Why?
|
| Xanthones | 1 | 2016 | 11 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 334 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 159 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2016 | 395 | 0.130 |
Why?
|
| Haploidy | 1 | 2016 | 32 | 0.130 |
Why?
|
| Paramyxoviridae | 1 | 2015 | 10 | 0.130 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2016 | 45 | 0.130 |
Why?
|
| Genetic Engineering | 1 | 2016 | 115 | 0.130 |
Why?
|
| Community-Acquired Infections | 1 | 2015 | 65 | 0.120 |
Why?
|
| Immunity | 1 | 2016 | 141 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 98 | 0.120 |
Why?
|
| Lymphocyte Subsets | 2 | 2013 | 66 | 0.120 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 107 | 0.120 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 167 | 0.120 |
Why?
|
| Immunologic Memory | 1 | 2016 | 164 | 0.120 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2015 | 131 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2011 | 952 | 0.120 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2014 | 20 | 0.120 |
Why?
|
| Survival Rate | 4 | 2014 | 1899 | 0.120 |
Why?
|
| Mice, Transgenic | 3 | 2013 | 1576 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 374 | 0.120 |
Why?
|
| Antigens, CD34 | 4 | 2017 | 159 | 0.110 |
Why?
|
| Inflammation | 1 | 2020 | 981 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2012 | 50 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 1983 | 0.110 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2013 | 20 | 0.110 |
Why?
|
| Interferon-beta | 1 | 2014 | 126 | 0.110 |
Why?
|
| Haplotypes | 2 | 2013 | 637 | 0.110 |
Why?
|
| Interleukin-18 | 1 | 2013 | 26 | 0.110 |
Why?
|
| Glucocorticoids | 1 | 2015 | 357 | 0.110 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 86 | 0.110 |
Why?
|
| Young Adult | 7 | 2017 | 6409 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 280 | 0.110 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2013 | 30 | 0.110 |
Why?
|
| Alemtuzumab | 3 | 2011 | 88 | 0.110 |
Why?
|
| Transplantation, Haploidentical | 3 | 2017 | 28 | 0.110 |
Why?
|
| Epothilones | 1 | 2013 | 12 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2016 | 398 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2016 | 423 | 0.100 |
Why?
|
| Prostate | 1 | 2016 | 407 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 354 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 293 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2010 | 1704 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 2 | 2015 | 1048 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 605 | 0.100 |
Why?
|
| Hematopoiesis | 1 | 2013 | 168 | 0.100 |
Why?
|
| Translocation, Genetic | 2 | 2019 | 264 | 0.100 |
Why?
|
| Tissue Donors | 2 | 2012 | 505 | 0.100 |
Why?
|
| Cell Movement | 2 | 2016 | 787 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 586 | 0.090 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 6783 | 0.090 |
Why?
|
| Graft Survival | 2 | 2013 | 908 | 0.090 |
Why?
|
| Leukocyte Transfusion | 1 | 2010 | 15 | 0.090 |
Why?
|
| Hospitalization | 1 | 2016 | 888 | 0.090 |
Why?
|
| Cell Survival | 1 | 2013 | 983 | 0.090 |
Why?
|
| Incidence | 3 | 2015 | 1603 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2010 | 57 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2016 | 1076 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 198 | 0.080 |
Why?
|
| Interleukin-2 | 1 | 2010 | 241 | 0.080 |
Why?
|
| Stem Cell Transplantation | 2 | 2020 | 189 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2010 | 466 | 0.080 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 397 | 0.080 |
Why?
|
| Chimerism | 2 | 2020 | 37 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2887 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2015 | 979 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2010 | 2000 | 0.070 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 174 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2009 | 520 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 317 | 0.070 |
Why?
|
| Melanoma | 1 | 2011 | 471 | 0.070 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 178 | 0.070 |
Why?
|
| Cyclosporine | 1 | 2007 | 238 | 0.070 |
Why?
|
| Lymphopenia | 1 | 2006 | 30 | 0.070 |
Why?
|
| Models, Animal | 1 | 2007 | 277 | 0.070 |
Why?
|
| Time Factors | 2 | 2013 | 5358 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 250 | 0.060 |
Why?
|
| Protein Binding | 1 | 2009 | 1491 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 2006 | 269 | 0.060 |
Why?
|
| Disease Progression | 1 | 2009 | 1469 | 0.060 |
Why?
|
| Prognosis | 4 | 2018 | 3798 | 0.060 |
Why?
|
| Age Factors | 3 | 2015 | 1880 | 0.060 |
Why?
|
| Mutation | 1 | 2015 | 4168 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 872 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 557 | 0.050 |
Why?
|
| Histocompatibility Testing | 2 | 2017 | 137 | 0.050 |
Why?
|
| Adolescent | 3 | 2016 | 9340 | 0.050 |
Why?
|
| Risk Factors | 3 | 2018 | 5558 | 0.050 |
Why?
|
| Illinois | 2 | 2012 | 485 | 0.040 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 22 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 1452 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 56 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 65 | 0.040 |
Why?
|
| Vincristine | 1 | 2019 | 111 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2012 | 1169 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 278 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2020 | 4329 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 84 | 0.040 |
Why?
|
| Etoposide | 1 | 2019 | 206 | 0.040 |
Why?
|
| Prednisone | 1 | 2019 | 255 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 94 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2019 | 262 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 301 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 263 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 293 | 0.040 |
Why?
|
| Premedication | 1 | 2017 | 57 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2017 | 45 | 0.040 |
Why?
|
| Palliative Care | 1 | 2019 | 264 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 276 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 281 | 0.040 |
Why?
|
| Cause of Death | 1 | 2018 | 269 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 864 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 785 | 0.030 |
Why?
|
| Receptors, CCR7 | 1 | 2016 | 16 | 0.030 |
Why?
|
| B7-2 Antigen | 1 | 2016 | 40 | 0.030 |
Why?
|
| CD8 Antigens | 1 | 2016 | 82 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2016 | 65 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 855 | 0.030 |
Why?
|
| U937 Cells | 1 | 2015 | 32 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 35 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 682 | 0.030 |
Why?
|
| Terminal Care | 1 | 2016 | 137 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 953 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2015 | 142 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1250 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 485 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2013 | 54 | 0.030 |
Why?
|
| Bortezomib | 1 | 2013 | 80 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 198 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 31 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 28 | 0.030 |
Why?
|
| CpG Islands | 1 | 2013 | 158 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2013 | 259 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2013 | 178 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 99 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 1091 | 0.030 |
Why?
|
| Pyrazines | 1 | 2013 | 91 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 276 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2013 | 99 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2013 | 211 | 0.030 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 29 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2011 | 53 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2010 | 71 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 277 | 0.020 |
Why?
|
| Family | 1 | 2012 | 324 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 657 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 740 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 495 | 0.020 |
Why?
|
| DNA | 1 | 2015 | 1311 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1732 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2016 | 1664 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2011 | 550 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 2886 | 0.020 |
Why?
|
| Genes, RAG-1 | 1 | 2006 | 13 | 0.020 |
Why?
|
| Lewis X Antigen | 1 | 2006 | 9 | 0.020 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2006 | 16 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2006 | 169 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2006 | 35 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 106 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2006 | 80 | 0.020 |
Why?
|
| Gene Library | 1 | 2006 | 132 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2006 | 391 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 206 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2005 | 149 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 693 | 0.010 |
Why?
|
| Cytokines | 1 | 2006 | 811 | 0.010 |
Why?
|
| Computational Biology | 1 | 2006 | 551 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 1066 | 0.010 |
Why?
|
| RNA | 1 | 2006 | 583 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 2026 | 0.010 |
Why?
|
| Apoptosis | 1 | 2006 | 1718 | 0.010 |
Why?
|